Kadant To Replace Inari Medical In S&P SmallCap 600
Written by Emily J. Thompson, Senior Investment Analyst
Source: NASDAQ.COM
S&P SmallCap 600 Update: Kadant Inc. will replace Inari Medical Inc. in the S&P SmallCap 600 index effective February 19, as Inari Medical is being acquired by Stryker Corp.
Acquisition Details: The acquisition of Inari Medical by Stryker Corp. is expected to be completed soon, pending final closing conditions.
Analyst Views on KAI
Wall Street analysts forecast KAI stock price to rise over the next 12 months. According to Wall Street analysts, the average 1-year price target for KAI is 360.00 USD with a low forecast of 340.00 USD and a high forecast of 380.00 USD. However, analyst price targets are subjective and often lag stock prices, so investors should focus on the objective reasons behind analyst rating changes, which better reflect the company's fundamentals.
3 Analyst Rating
2 Buy
1 Hold
0 Sell
Moderate Buy
Current: 327.280
Low
340.00
Averages
360.00
High
380.00
Current: 327.280
Low
340.00
Averages
360.00
High
380.00
About KAI
Kadant Inc. is a global supplier of technologies and engineered systems that drive sustainable industrial processing. The Company’s segments include Flow Control, Industrial Processing, and Material Handling. Its Flow Control segment provides custom-engineered products, systems, and technologies that control the flow of fluids used in industrial and commercial applications to keep critical processes running efficiently in the packaging, tissue, food, metals, energy, and other industrial sectors. Its Industrial Processing segment provides equipment, machinery, and technologies used to recycle paper and paperboard and process timber for use in the packaging, tissue, wood products and alternative fuel industries, among others. Its Material Handling segment provides products and engineered systems used to handle bulk and discrete materials for secondary processing or transport in the aggregates, mining, food, and waste management industries, among others.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
